Drugs / Deproteinized bovine bone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02612740 | Apr 2010 → Dec 2014 | cysts and fistulae of the face and oral cavity | University of Padova, School of Dental Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-09-19 | Geistlich Pharma AG | Results Good long-term results for implants using GBR with membranes geistlich.com ↗
The cumulative implant survival rate at follow-up was 93.2%, without any significant differences between the three groups. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-09-30 | Geistlich Pharma AG | Success for Geistlich Pharma in trademark law dispute relating to Bio-Oss® geistlich.com ↗ |
| 2013-09-19 | Geistlich Pharma AG | Good long-term results for implants using GBR with membranes geistlich.com ↗ |
| 2013-03-12 | Geistlich Pharma AG | IDS 2013: Extraction sockets, the new Geistlich Bio-Oss Pen® and spectacular 3D surgical movies geistlich.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deproteinized bovine bone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02612740 ↗ |
| Known as | Bio-Oss | “granules of deproteinized bovine bone (Bio-Oss)” NCT02612740 ↗ |